Related references
Note: Only part of the references are listed.FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice
Giustina Ferone et al.
CELL REPORTS (2020)
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand
Alberto D'Angelo et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
Molly R. Ryan et al.
MOLECULAR CANCER RESEARCH (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Daichao Wu et al.
CHEMICAL COMMUNICATIONS (2018)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Jharna Datta et al.
MOLECULAR CANCER THERAPEUTICS (2017)
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
Cheng Mo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
Donglou Liang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
Yuta Adachi et al.
CARCINOGENESIS (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors
Barbara Rivera et al.
ACTA NEUROPATHOLOGICA (2016)
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
Masaaki Hibi et al.
CANCER SCIENCE (2016)
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers
Kyle Dyson et al.
HISTOPATHOLOGY (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles' Heel of Targeted Therapy
Christal D. Sohl et al.
ACS CHEMICAL BIOLOGY (2015)
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
Konstantin Agelopoulos et al.
CLINICAL CANCER RESEARCH (2015)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
Xiaomei Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
Ezia Bello et al.
CANCER RESEARCH (2011)
Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
Kevin B. Kim et al.
CLINICAL CANCER RESEARCH (2011)
The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion
Masahiro Onozawa et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
S Roumiantsev et al.
CANCER CELL (2004)
Share Paper
